Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Blood Cancer Discovery|July 9, 2025
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
Blood Cancer Discovery|August 8, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
The New England Journal of Medicine|June 15, 2026
Talquetamab-Daratumumab in Relapsed or Refractory MyelomaRoberto Mina, Meral Beksac, Paula Rodríguez-Otero, et al.
The New England Journal of Medicine|June 6, 2022
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G Richardson, Susanna J Jacobus, Edie A Weller, et al.
Pageof 10